Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
about
Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8+ T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma.Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for ManagementDetection of a novel, primate-specific 'kill switch' tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53The age of enlightenment in melanoma immunotherapy
P2860
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Nivolumab Plus Ipilimumab in P ...... Phase I Dose-Escalation Study.
@en
Nivolumab Plus Ipilimumab in P ...... Phase I Dose-Escalation Study.
@nl
type
label
Nivolumab Plus Ipilimumab in P ...... Phase I Dose-Escalation Study.
@en
Nivolumab Plus Ipilimumab in P ...... Phase I Dose-Escalation Study.
@nl
prefLabel
Nivolumab Plus Ipilimumab in P ...... Phase I Dose-Escalation Study.
@en
Nivolumab Plus Ipilimumab in P ...... Phase I Dose-Escalation Study.
@nl
P2093
P2860
P356
P1476
Nivolumab Plus Ipilimumab in P ...... Phase I Dose-Escalation Study.
@en
P2093
Alexander Lesokhin
Christine Horak
Harriet Kluger
Jedd D Wolchok
John M Kirkwood
Margaret K Callahan
Michael A Postow
Michael B Atkins
Neil H Segal
Rafia Bhore
P2860
P304
P356
10.1200/JCO.2017.72.2850
P407
P50
P577
2017-10-17T00:00:00Z